Omalizumab Treats Aspirin-Induced Asthma Complicated With Nasosinusitis and Otitis Media:Report of One Case / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
; (6): 699-702, 2023.
Article
Dans Zh
| WPRIM
| ID: wpr-1008120
Responsable en Bibliothèque :
WPRO
ABSTRACT
Omalizumab,as a biological agent targeting IgE,is a recombinant humanized monoclonal antibody and the first targeted drug approved for treating moderate-to-severe bronchial asthma.By reviewing one case of aspirin-induced asthma complicated with nasosinusitis and otitis media,we discussed the value of omalizumab in the treatment of asthma and its complications,aiming to provide a reference for clinical practice.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Otite moyenne
/
Asthme
/
Asthme induit par l'aspirine
/
Omalizumab
Limites du sujet:
Humans
langue:
Zh
Texte intégral:
Acta Academiae Medicinae Sinicae
Année:
2023
Type:
Article